Introduction
Refinements in cardiac imaging modalities are influencing the understanding and management of cardiac amyloidosis (CA). In transthyretin cardiac amyloidosis (ATTR-CA), a disease predominantly affecting elderly adults [1] , transthyretin protein (TTR), a liver-synthesized tetramer, destabilizes into its component monomers, which misfold and aggregate into amyloid fibrils. Extracellular cardiac deposition of fibrils from either wild-type (ATTRwt) or mutated TTR (ATTRm) disrupts tissue architecture causing diastolic dysfunction, heart failure, eventual systolic dysfunction, and death [2] .
Several advanced cardiac imaging modalities for ATTR-CA have evolved including advanced echocardiographic tissue Doppler (TDI) and speckle-tracking imaging (STI), cardiac magnetic resonance imaging (CMR), bone isotope imaging with technetium (Tc99m)-based isotopes, and positron emission tomography (PET). While regional and center-related practices may influence the choice of cardiac imaging modality that is used, clinicians could further refine standard of care by first establishing a clear ATTR-CA diagnostic and management goal and then pairing the best available modality optimized to achieve that specific goal.
Diagnostic goals for ATTR-CA include raising suspicion of the diagnosis, making a definitive diagnosis, preferably early in the disease course before overt heart failure ensues, and identifying amyloid subtype. Management goals include assessment of ventricular impairment, prognostication, and monitoring disease progression [3] . With numerous diseasemodifying therapies currently in development, selecting the optimal cardiac imaging modality to achieve each goal will become increasingly important [4] . Furthermore, given the demographics of ATTR-CA, it is important to understand the challenges and considerations unique to the elderly population when selecting imaging modalities. The present article reviews the utility and application of advanced cardiac imaging modalities for each diagnostic and management goal in the older patient with ATTR-CA (Fig. 1) .
Epidemiology
In the USA,~26% of the population is ≥65 years of age, a proportion which has more than doubled since 2010 [5] , and which accounts for more than half of all cardiovascular hospitalizations and~80% of cardiovascular deaths [6] . As the population ages, the prevalence of ATTR-CA will climb, given its age-dependent penetrance. Advances in non-invasive cardiac imaging have facilitated diagnosis of cardiac amyloidosis and have demonstrated that ATTRwt is not as rare as previously thought [7] . Among elderly adults hospitalized with heart failure with a preserved ejection fraction (HFpEF) of ≥50% and a left ventricular (LV) wall thickness >12 mm, the incidence of ATTR-CA was 13.3%, a proportion that likely underestimates its true burden given that the study preselected a specific wall thickness threshold that may not capture patients with borderline LV hypertrophy [8] . Amyloid deposition may not be heralded initially by increased wall thickness, and hence, a focus on increased wall thickness as a screening criterion may underestimate true prevalence. Data from the Transthyretin Amyloid Outcomes Survey (THAOS), a global observational database of patients with ATTR, revealed that approximately 48% of patients with ATTR-CA in the USA have ATTRwt. This was followed by 23% with ATTRm due to a valine-to-isoleucine substitution at position 122 (Val122Ile), a mutation present almost exclusively in African Americans with an allele frequency of~4% [1, 9] . The most commonly encountered CA subtypes in elderly adults are ATTRwt, followed by ATTRm, and light-chain (AL) [2] .
ATTR-CA Diagnostic and Management Goals in Elderly Adults

Raising Clinical Suspicion
Conventionally, standard transthoracic echocardiography (TTE) is often the first imaging modality to raise suspicion for CA. TTE is safe and easy to perform in the elderly population. Typical echocardiographic features of CA include left ventricular (LV) and right ventricular (RV) wall thickening without an explanatory stimulus (i.e., hypertension or valvular disease, specifically aortic stenosis) [10] , bi-atrial enlargement, thickening of the interatrial septum, and the presence of a pericardial effusion [11] [12] [13] [14] . Diastolic dysfunction is common [13, 15] and often advanced, typically with a restrictive filling pattern with high early (E) and relatively low atrial (A) wave with an E/A ratio >2, and a short deceleration time [10, 13, 15] . The myocardium may have a "granular sparkling" or "speckled" appearance [13] . In a recent study using the THAOS registry [16] , 59% of patients with ATTR (252/ 425) were found to have an IVS ≥ 13 mm, thereby meeting the International Consensus Criteria for cardiac amyloidosis [17] . Of these patients with ATTR-CA, 49% had a LV ejection fraction (EF) <50%, 77% had RV thickening >7 mm, 79% had left atrial dilation >40 mm, 66% had myocardial sparkling, 37% had aortic valvular thickening, 44% had mitral valvular thickening, and 18% had a restrictive filling pattern (E/A > 2) [16] . Poor RV function, as measured by decreased RV fractional shortening, low tissue Doppler S' of the RV free wall, and decreased tricuspid annular plane systolic excursion (TAPSE), may also be present in advanced disease [18] . Further studies using comparisons with controls and patients with LVH of other etiologies are required to determine the sensitivity and specificity of the above features.
In the elderly patient, it is the constellation of the above echocardiographic features and not any single parameter that typically elevates suspicion for ATTR-CA. Other causes of left ventricular hypertrophy (LVH), such as hypertension, hypertrophy due to increased central artery stiffness, aortic stenosis (AS), and hypertrophic cardiomyopathy (HCM), can present with similar TTE findings. Furthermore, TTE typically signals the possibility of ATTR-CA only after lifelong myocardial infiltration of amyloid fibrils [19] as it lacks sensitivity for detection of early myocardial infiltration. Therefore, TTE is a tool best applied in older adults for raising suspicion of late-stage, but usually not early disease [12, 13, 15] .
Advanced echocardiographic speckle-strain imaging (SSI) can raise suspicion for ATTR-CA earlier and with greater accuracy than conventional 2D TTE by detecting changes in regional myocardial deformation specific to amyloid. Impairments in strain may occur earlier in the pathophysiology of CA [13] than overt structural 2D TTE changes [15, 20, 21] and clinical heart failure [22, 23] . Compared to patients with other forms of LVH, patients with amyloid cardiomyopathy have significantly reduced longitudinal and radial strain [24, 25] and demonstrate a characteristic pattern of diminished global longitudinal strain (LS) in the basal and mid left ventricular segments with preserved strain in the apex [26] [27] [28] . In contrast, HCM may present with focally impaired global longitudinal strain in the specific myocardial segment known to be hypertrophied while strain in remaining segments remains normal [27] . In amyloid, apical sparing can occur irrespective of LVEF, degree of wall thickening (i.e., early in the course of CA), or amyloid subtype [20, 28] . Apical sparing can be quantified as the relative regional strain ratio (RRSR), calculated as the average apical LS/(average basal + mid LS) [27, 29] . In a cohort of 55 patients with confirmed CA, a RRSR >1 was 93% sensitive and 82% specific for CA compared to HCM or AS [27] . Likewise, a ratio of septal apical to basal segmental longitudinal peak systolic strain >2.1, in combination with shortened diastolic deceleration time of early filling <200 ms, differentiated CA from other causes of LVH (including hypertension, Fabry disease, and Friedreich ataxia) with a sensitivity of 88% and specificity of 85% [30] .
CMR can assess morphological and functional characteristics of myocardial tissue using specialized post-contrast techniques, including inversion recovery imaging for late gadolinium enhancement (LGE) and T1 mapping for fractionation of extracellular volume (ECV) [10, 31] . A shortened postcontrast T1 signal is seen in CA due to interstitial expansion by amyloid infiltration and subsequent gadolinium deposition. Patients with CA demonstrate characteristic patterns of LGE including global subendocardial [32] [33] [34] [35] [36] and transmural enhancement [37, 38] . A recent meta-analysis of five studies (257 patients) assessing the diagnostic accuracy of LGE assessment by CMR demonstrated a sensitivity of 85% and specificity of 92% for CA [39] .
CMR T1 mapping can analyze changes in myocardial longitudinal relaxation. Pre-contrast T1 signal was increased in 85 elderly patients with ATTR-CA (mean age 73) compared to 46 patients with HCM and 52 healthy controls [40] . In a cohort of 85 elderly patients with ATTR, 79 with AL, 46 with HCM, and 52 healthy controls, T1 elevations were found to have an area under the receiver operator characteristic curve (AUC) of 0.85 for distinguishing ATTR-CA or AL from HCM and healthy controls [40] . Pre-contrast and postcontrast T1 data can be used together to calculate the ECV, a measurement of interstitial expansion [34, 38] which is significantly elevated in patients with CA, due to interstitial amyloid deposition [31, 41] . In a study comparing 36 elderly patients with CA to 30 healthy controls, a cutoff of ECV >0.316 was 79% sensitive and 97% specific (AUC of 0.884) for CA [41] . Therefore, while CMR may be a reasonable tool for diagnosis of cardiac amyloid, it is usually performed to evaluate cardiomyopathy and the above findings are incidentally found, which ultimately raise suspicion but do not define the diagnosis.
CMR is safe, painless, and requires no radiation. However, its use may be limited in the elderly population, as select patients may have implanted ferromagnetic hardware or may not tolerate lying immobile for the duration of the examination due to comorbidities such as spinal stenosis or heart failure. Furthermore, for elderly patients with concomitant renal impairment, CMR protocols requiring the use of contrast may be contraindicated.
Diagnosis
Until recently, the gold standard for a definitive diagnosis of CA required endomyocardial biopsy and tissue typing with histological staining, immunohistochemistry, and mass spectrometry [10] . However, procedural risk in a frail elderly population and the need for pathologic expertise at experienced centers limits this approach and may delay the diagnosis. Recent advances in nuclear cardiac imaging have challenged this traditional paradigm and offer an alternative non-invasive diagnostic approach in selected patients.
Nuclear scintigraphy using bone isotope imaging has shown promise as a non-invasive method to diagnose ATTR-CA. Common isotopes used include technetium 3,3-diphosphono-1,2-propanodicarboyxylic acid (Tc99m-DPD), routinely used in Europe but not available in the USA, technetium pyrophosphate (Tc99m-PYP), Food and Drug Association (FDA) approved for use in the USA for bone imaging, also used in Canada and Japan, and technetium hydroxymethyleme diphosphonate (Tc99m-HMDP). Scintigraphy was first noted to visualize amyloid deposits in case studies in the 1970s and 1980s [42] [43] [44] ; however, the modality went quiescent due to a perceived lack of sensitivity for ATTR-CA, likely given heterogeneous study cohorts that included patients with both ATTR and AL cardiac amyloidosis [33] .
A revival in nuclear scintigraphy for CA was sparked in 2005 when Perugini et al. demonstrated that 15/15 patients with ATTR-CA had strong myocardial uptake of Tc99m-DPD whereas no uptake was observed in 10 patients with AL, suggesting 100% sensitivity and specificity for diagnosing ATTR-CA [33] . Subsequent studies confirmed high sensitivity and specificity for Tc99m-DPD in differentiating ATTR-CA from other causes of LVH using a semiquantitative visual score ranging from 0 to 3 (score 0 = absent cardiac uptake and normal bone uptake; 1 = mild cardiac uptake, inferior to bone uptake; 2 = moderate cardiac uptake with attenuated bone uptake; 3 = strong cardiac uptake with mild/absent bone uptake) [33, 45, 46] and a quantitative heart-to-whole body (H/WB) ratio, comparing uptake in the heart to the remainder of the body [47, 48] .
Like Tc99m-DPD, the North American isotope Tc99m-PYP, was shown to bind ATTR cardiac deposits with high affinity. In a cohort of 45 elderly patients with biopsy proven CA (16 ATTRwt, 17 ATTRm, and 12 AL), a visual score 2 or greater and a heart-to-contralateral chest (H/CL) ratio (comparing myocardial tracer uptake in the heart to an equivalent region in the contralateral chest) >1.5 was 97% sensitive and 100% specific for diagnosing ATTR-CA [49•] . High diagnostic accuracy was replicated in a subsequent multicenter study of 121 patients with biopsy proven ATTR-CA that demonstrated >90% sensitivity and specificity [50•] . The patient population included in these two studies, mean age 70 ± 2 and median age 73 (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) , reflects the near exclusivity of this diagnosis to the elderly population.
Tc99m-HMDP has also shown high diagnostic accuracy for detection of ATTR-CA [47, 51] . Increased uptake, assessed by an elevated heart-to-skull ratio, was found in 21/ 21 patients with ATTRwt, 24/26 patients with ATTRm, and 1/14 patients with AL; a visual score >2 was 100% specific for ATTR-CA [51] . A study of six patients with ATTR-CA (age [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] found comparable uptake intensity of Tc99m-HMDP and Tc99m-DPD, supporting the utility of Tc99m-HMDP in diagnosing ATTR-CA [52] .
In an international multicenter collaboration among 857 patients with CA who had undergone Tc99m-DPD, Tc99m-PYP, or Tc99m-HMDP radioisotope scintigraphy, grade 2 or 3 myocardial uptake was found to be 100% specific for the diagnosis of ATTR-CA in patients with no evidence of an abnormal monoclonal protein [53••] . This led to the international consensus that in select patients without evidence of an abnormal monoclonal protein, a positive radioisotope nuclear scan can diagnose ATTR-CA without the need for biopsy.
Nuclear imaging is therefore an accurate and feasible imaging modality that may spare select elderly patients the need for invasive biopsy. Scans are faster than CMR, though they do require a supine position and minimal radiation exposure. Recently, a standardized protocol for Tc99m-PYP was published (45 patients, mean age 70 ± 2) with a faster incubation period (1 h vs. 2-4 h), less radiation exposure compared to other protocols (3 mSv vs. 8-10 mSv), and only 10 min under the camera [54] .
PET radiotracers have also demonstrated an affinity for amyloid fibrils and may aid in the diagnosis of CA. Several radiotracers have been studied, including 11C-Pittsburgh compound B (PIB), (18)F-florbetapir, and (18)F-florbetaben. 11C-PIB myocardial uptake was found to be elevated in 10/10 patients with CA (7 AL, 3 ATTR, mean age 66) with no uptake in five controls [55] . Subsequent studies found equally promising results with significant myocardial 11C-PIB uptake in 10/10 patients with ATTRm (V30M) [56] and even in patients who had ATTR with peripheral neurologic disease without known cardiac involvement [56] .
(18)F-florbetapir, (18)F-florbetaben, and (18)F-sodium floride (NaF) have also shown potential in diagnosing CA. (18)F-florbetapir myocardial uptake was elevated in 9/9 patients with CA (4 ATTR-CA, 5 AL) but not in amyloidnegative controls [57] . An autopsy study showed that all myocardial sections of patients with CA (10 ATTR-CA, 10 AL) had elevated uptake of (18)F-florbetapir compared to controls [58] . (18)F-florbetaben also localized to myocardial amyloid fibrils in ten patients with CA (5 ATTR-CA, 5 AL) with no uptake seen in four controls with LVH secondary to longstanding hypertension [59] . (18)F-NaF may be of benefit in diagnosing ATTR-CA as well. In a cohort of seven subjects (2 ATTRwt, 2 ATTRm, 3 AL), (18)F-NaF uptake was elevated in all patients with ATTR but in no patients with AL or seven non-amyloid controls [60] , indicating specificity for ATTR.
PET imaging is a reasonable and safe option in the elderly population. In fact, research into the utility of PET for CA was sparked by evidence that 11C-PIB, (18)F-florbetapir, and (18)F-florbetaben can be useful in the diagnosis of dementia, a disease that predominantly affects elderly adults [61] . While patients must assume a supine position, a potential limiting factor in select older patients with orthopedic spine problems, the duration of the supine part of the examination lasts approximately 20 min, which is less than for most MRI protocols.
Early Diagnosis
Early detection of ATTR-CA, before the disruption of tissue architecture and organ failure, remains an important clinical goal, especially given that emerging disease-modifying therapies can prevent disease progression but do not reverse existing damage [62] . Therefore, employment of cardiac imaging to detect ATTR-CA early will be essential to identify patients who would benefit from early intervention before late-phase cardiac impairment occurs. Clinical clues in asymptomatic patients may include increased family history of cardiac amyloidosis, increased wall thickness, peripheral neuropathy, a history of carpal tunnel syndrome and/or orthopedic surgery for bilateral carpal tunnel surgery, or degenerative lumbar spinal stenosis.
Abnormal patterns of LGE on CMR were found to occur before increases in LV wall thickness and other late echocardiographic signs of amyloid infiltration [34, 63] , with one study demonstrating abnormal LGE in 17/36 of patients with suspected amyloidosis without LV wall thickening [34] . Patchy intramural focal LGE on CMR has also been associated with less severe CA than global subendocardial or transmural enhancement [34] .
Nuclear scintigraphy may also be useful for the early diagnosis of CA. In elderly cohorts, both Tc99m-DPD and Tc99m-PYP detected ATTR-CA before any evidence of cardiac involvement on TTE [45, 47, 48, 64] . 99mTc-DPD cardiac uptake was found in 12 patients with ATTR (4 ATTRwt, 8 ATTRm) who had no echocardiographic evidence of cardiac involvement by wall thickness [45] . In another study, among 12 patients with ATTRm and no evidence of infiltrative cardiomyopathy by normal TTE and biomarkers (N-terminal pro b-type natiuretic peptide [NT-proBNP], troponin-I), 10/12 had some abnormal Tc99m-PYP uptake and 7/12 had diagnostic levels of tracer uptake (grade 2 or 3) [64] . Although myocardial radiotracer uptake in these asymptomatic patients was lower than that seen in patients with ATTRm-related heart failure, it was significantly higher than in patients with nonATTRm-related HFpEF, suggesting a role for Tc99m-PYP nuclear scintigraphy for early detection of ATTR-CA.
Preliminary data suggest that PET cardiac imaging may also play a role in early diagnosis. Of ten patients with ATTRm (V30 M), mean age 68.7 years, with primary neurological manifestations of ATTR, 11C-PIB myocardial PET detected abnormal cardiac uptake in all patients, indicating cardiac involvement before overt heart failure symptoms [56] .
Subtyping
Differentiating between AL and ATTR-CA is crucial, as the prognosis for AL is worse than ATTR-CA [2] and the therapeutic options for AL (including chemotherapy and stem cell transplantation) have no role and may be harmful if given to a patient with ATTR-CA.
Among the non-invasive cardiac imaging modalities studied to date, nuclear scintigraphy has demonstrated strong evidence for accurate subtyping given the preferential affinity of these agents for TTR amyloid fibrils [33, 45, 46, 49•, 51, 52, 65] . In 45 elderly patients with biopsy proven CA (16 ATTRwt, 17 ATTRm, 12 AL, mean ages 77, 70, 63, respectively), a Tc99m-PYP H/CL ratio > 1.5 was found to be 97% sensitive and 100% specific for distinguishing ATTR-CA from AL [49•] . In a multicenter study of 171 elderly patients, median age 73 (65--79) , (121 ATTR-CA, 34 AL, 16 nonamyloid HFpEF), a Tc99m-PYP H/CL ratio of ≥1.5 in subjects scanned after 1 h radioisotope incubation (and ≥1.3 for 3 h incubation) was 91% sensitive and 92% specific for detecting ATTR-CA and differentiating it from AL [50•]. False positives were typically patients with AL who had traces but not insignificant myocardial radiotracer uptake or in patients with AL and focal uptake suggesting a history of myocardial infarction. The multicenter international collaboration in patients with CA who had undergone Tc99m-DPD, Tc99m-PYP, or Tc99m-HMDP, demonstrated that a positive nuclear scan with myocardial uptake of grade 2 or higher and the absence of an abnormal monoclonal protein (ruling out AL) was 100% specific for ATTR-CA [53••] .
Recent reports using PET imaging have demonstrated promise in subtyping CA [66] [67] [68] . In a case study using (18)F-NaF, also a bone seeking tracer, diffuse myocardial enhancement was observed in a patient with ATTRm (Val122Ile) with no uptake in a patent with AL [66] . In a study of seven elderly patients with CA (three ATTRwt, two ATTRm-V122I, 2 AL, mean age 71.1), qualitative and quantitative (18)F-NaF uptake was significantly increased in ATTR-CA and absent in controls and patients with AL, further suggesting a role for (18)F-NaF in subtyping [67] . However, another case report of two patients with ATTR-CA (1 ATTRwt and 1 ATTRm-Ile68Leu) demonstrated no cardiac uptake of (18)F-NaF in either patient. The authors concluded that the presence and type of ATTR mutation may influence (18)NaF tracer uptake [68] . A recent study of (18)Fflorbetapir uptake in myocardial autopsy specimens (ten AL, ten ATTR, ten controls) found increased uptake in all CA patients and no controls, with uptake greater in AL than ATTR [58] , while another study demonstrated increased liver uptake of (18)F-florbetapir in AL and normal liver uptake in ATTR-CA [69] , suggesting that (18)F-florbetapir may preferentially bind AL fibrils.
TTE has demonstrated limited utility in subtyping amyloid since ATTRwt, ATTRm, and AL all share similar echocardiographic features, though data from one study suggested that CMR may have a role. Among 97 patients with CA (51 ATTR-CA, 46 AL, mean age 68), a scoring system using a logistic regression model including LGE, age, and wall thickness was 87% sensitive and 96% specific for differentiating ATTR-CA from AL [37] .
Despite lack of data supporting the utility of 2D TTE, strain, and CMR to accurately subtype CA, these modalities have revealed subtle differences between subtypes. By TTE comparisons of 15 ATTRwt, 61 ATTRm, and 157 AL patients, one study demonstrated that mean LV and IVS wall thickness was greatest in patients with ATTRwt, followed by ATTRm, and AL (mean LV wall thickness-18.8 mm vs. 16.0 mm vs. 15.2 mm, p < 0.0001; IVS 19.7 mm vs. 16.6 mm vs. 15.8 mm, p < .0001) [2] ; subsequent studies have replicated these findings [20, 49•, 70, 71] . While apical strainsparing on SSI is found among all CA subtypes [20, 28] , a study of 172 patients (56 ATTRwt, 36 ATTRm, 80 AL), showed that patients with ATTRwt and AL had worse LS than patients with ATTRm [20] and another demonstrated that elderly patients with ATTRwt had worse radial and circumferential strain than elderly patients with ATTRm [72] . CMR studies have demonstrated that patients with ATTR-CA, and ATTRwt in particular, had greater LV mass [37, 70] and were more likely to have RV LGE than patients with AL [37] . Additional studies are required to determine whether LGE patterns (subendocardial vs. transmural) relate to CA subtype [31, 37] . Together, these differences suggest that ATTRwt is usually diagnosed later with greater myocardial deposition of amyloid compared to ATTRm and AL, perhaps related to the lower myocardial toxicity of TTR deposits than those of AL.
Once echocardiography or CMR have elevated clinical suspicion for CA, the above metrics can help delineate subtle anatomic differences but should not be used for the purpose of subtyping disease.
Assessment of Ventricular Impairment
Evaluating the degree of ventricular functional impairment in elderly patients with CA is an important management goal not only to gain insight into functional status but also to risk stratify and determine the appropriateness of specific forthcoming therapies. Accurately quantifying amyloid burden may also aid in determining disease severity. As endomyocardial biopsy is prone to sampling error and therefore may not accurately quantify myocardial amyloid burden, non-invasive approaches may capture a more clinically relevant picture.
Conventional echocardiographic techniques play an important role in functional assessment, measuring wall thickness and LVEF, as well as identifying patterns of diastolic dysfunction and restrictive physiology. These indices are important markers of disease severity, but conventional echocardiography is limited in its ability to detect and stratify early functional impairment. Strain echocardiography can detect impairments in myocardial function before overt systolic or diastolic dysfunction are detected on standard TTE [15] . Impairments in LS also correlate with impaired LVEF [23, 28] , increased wall thickness [20] , and LGE on CMR [26, 28] in later stages of disease.
On CMR, patterns of LGE reflect different stages of disease severity and may offer clues as to the degree of myocardial involvement. Patchy intramural focal enhancement is typically seen in less severe disease, while global subendocardial LGE is associated with increasing disease severity (i.e., worse heart failure symptoms, ECG changes, and elevated troponin-T and BNP) [34] , and transmural LGE represents advanced disease. Transmural LGE is associated with a host of markers of functional impairment including low systolic blood pressure, conduction disease, elevated NT-proBNP, increased wall thickness, severe diastolic dysfunction, and decreased functional capacity on a 6-min walk test [38] . Additionally, the degree of native T1 elevation [38, 40] and ECV expansion [31, 38] both correlate with disease severity. Increasing ECV has been associated with depressions in systolic function, increased wall thickness, worsening diastolic dysfunction, and elevations in NT-proBNP and troponin-I [41] . Increasing ECV was also associated with increasing LGE on CMR (a progression of none to subendocardial to transmural enhancement) and increasing Tc99m-DPD visual grade (all comparisons p < .0001) [38] .
Nuclear scintigraphy may also aid in the functional assessment of the elderly patient diagnosed with ATTR-CA as the degree of radiotracer uptake has correlated with markers of disease severity. In elderly patients with ATTR-CA, an increased Tc99m-DPD H/WB ratio correlated with increased cardiac biomarkers, renal failure, increased wall thickness and LV mass index, worse LVEF, diastolic dysfunction, and low mitral annular plane systolic excursion, an echocardiographic measure of longitudinal systolic dysfunction [47, 48, 73, 74 ]. An increased Tc99m-HMDP heart to skull ratio correlated with increased cardiac biomarkers and worse LVEF [51] . And among elderly patients with ATTR-CA, a Tc99m-PYP H/CL ratio of >1.6 vs. <1.6 was associated with lower LVEF, increased IVS thickness, lower stroke volume, and a lower myocardial contraction fraction, a ratio of stroke volume to myocardial volume [50•] that has been associated with worse survival in patients with AL amyloid [75] .
PET imaging has shown preliminary promise in quantifying disease burden. A recent study demonstrated that the percent of (18)F-florbetaben uptake was an independent determinant of LV and RV LS [59] . More data is required, as PET tracers are in early phases of evaluation for ATTR-CA.
Prognostication
Recently, a three-tier staging system was developed to predict overall survival of patients with ATTRwt using the biomarker cutoffs troponin-T >0.5 ng/mL and NT-proBNP >3000 pg/ mL. Median survival was 66 months for patients with both biomarker values below threshold (Stage I), 40 months for patients with one value above threshold (Stage II), and 20 months for patients with both biomarkers above threshold (Stage III) [76] . In addition to biomarkers, cardiac imaging techniques have also been shown to inform prognosis in elderly patients with ATTR-CA.
2D TTE features, including systolic and diastolic dysfunction, as well as restrictive filling patterns have been associated with worse outcomes [77, 78] . Among all CA subtypes, a TAPSE <14 mm predicted major adverse cardiac events (MACE), including acute decompensated heart failure, orthotopic heart transplantation, and death [18] . Strain assessment of 172 patients with CA (56 ATTRwt, 36 ATTRm, 80 AL, mean age 66) demonstrated that impaired LV basal LS was independently associated with all-cause mortality [20] . Of 97 patients with CA (38 ATTR 59 AL, mean age 64), a higher RRSR (indicating more basal and mid ventricular strain impairment relative to the apex) predicted MACE [29] .
Global subendocardial LGE on CMR correlated with worse New York Heart Association (NYHA) functional class, elevated troponin-T and BNP [34] , and death [36, 79] and a transmural LGE pattern independently predicted death [38] . In elderly patients with ATTRwt, increased LV mass and maximal apical wall thickness on CMR also independently predicted worse outcomes [70] , and among all CA subtypes, a hypointense T2 signal predicted worse survival [80] .
Nuclear scintigraphy may also be helpful in prognosticating survival in elderly patients diagnosed with ATTR-CA. While a recent study demonstrated that stratification by the semiquantitative visual score of Tc99m-DPD uptake, derived by Perugini et al., did not assist in prognosticating [81] , quantitative assessments have been more successful. Among 63 patients with hereditary ATTR-CA, increased myocardial uptake of Tc99m-DPD using the heart-to-whole body ratio in conjunction with mean LV wall thickness >12 mm was associated with worse MACE-free survival [48] . In a study of 55 patients with ATTR-CA and 14 with AL, increased myocardial retention of Tc99m-HMDP using the heart to skull ratio >1.94 was associated with increased acute heart failure and/or death [51] . And finally, among 121 patients with biopsy proven ATTR pooled from three centers in the USA, despite a referral population with high pre-test probability of disease and the employment of two scan protocols, a ratio of 1.6 or greater of Tc99m-PYP uptake was associated with worse survival [50•] .
Monitoring Disease Progression and Assessing Response to Therapy
Among elderly adults with ATTR-CA, general treatment principles include maintaining euvolemia, avoiding symptomatic hypotension, and assessment for pacemaker therapy in those with clinically significant conduction disease [4] . Select patients with advanced disease may undergo heart transplant; however, many elderly patients with ATTR-CA are beyond institutional age cutoffs at the time of diagnosis or may have other comorbidities that preclude them from transplantation. Disease-modifying therapies for ATTR-CA are under active clinical investigation and include TTR stabilizers, silencers, and amyloid-degrading therapies [4] . In a phase 2 trial of 31 patients with ATTRwt (mean age 76.7), 30/31 patients treated with Tafamidis achieved TTR stabilization after 6 weeks, and of the 28 patients that completed therapy for 1 year, NTproBNP levels and echocardiographic findings remained unchanged, and 20/28 patients maintained the same NYHA functional class [82] . Though no agents are currently FDA approved for ATTR-CA, a new era in the treatment of this disease is rapidly approaching [4, 83] and, with it, the need for cardiac imaging to effectively monitor therapeutic response. Cardiac imaging in the elderly will be needed to quantify the degree of pre-and post-treatment myocardial amyloid and associated functional impairment and therefore is likely to play a significant role in monitoring response to emerging therapies for ATTR-CA.
Conclusions
A host of advanced, non-invasive cardiac imaging modalities are now available to not only provide an accurate diagnosis of ATTR-CA in elderly adults with suspected disease but also to aid in early diagnosis, amyloid subtyping, assessment of cardiac functional impairment, prognosticating disease severity, and soon, tracking response to therapy. Selecting the appropriate non-invasive imaging modality will be essential for optimal patient care in the elderly patient with ATTR-CA as we enter an era of enhanced recognition, earlier diagnosis, and potential therapeutics. Dr. Manson declares no conflicts of interests. Dr. Mathew S. Maurer receives funding from an NIH K24 AG036778 Midcareer Mentoring Award in Geriatric Cardiology and his institution receives funding for research and serving on advisory boards and DSMBs from Pfizer Inc., Alnylam Pharmaceuticals Inc., ISIS Pharmaceuticals, and Prothena Inc.
Dr. Bokhari declares no conflicts of interests.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
